Regenerating the rotator cuff tendon-to-bone interface through biofabrication

通过生物制造再生肩袖肌腱与骨骼的界面

• 批准号: 2890262
• 金额: --
• 依托单位: University of Manchester
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2890262
• 关键词: Regenerating; rotator; cuff; tendon; bone

Shoulder pain affects approximately 20% of the population at any one time. A tear in the rotator cuff tendon accounts for 40% of the causes of shoulder pain. The current gold standard treatment for rotator cuff tendon tears in the shoulder is surgical repair. However, surgical repair of the degenerate tendon can fail due to lack of tendon healing in 22% of cases. This risk of failure doubles in incidence between 50 and 70 years. Thus, there is a disconnect between current treatment methods and the underlying pathology as mechanical suturing of the degenerate tendon to bone leads to failure for a high proportion of patients. This project aims to deliver a new scaffold-based therapy with enhanced biological properties to support the functional regeneration of the torn tendon and improve healing rates. Building on previous work we will produce biomaterials from bacterial origin (i.e. Polyhydroxyalcanoates - PHAs) with tuneable composition and anti-bacterial features to mimic the biological, chemical and physical properties of native bone/tendon tissues. To improve biomechanical coupling at the defect site and enhance functional regeneration, we will fabricate scaffolds with imprinted functional gradients capable of replicating the native tendon/bone interface. This will be achieved using multi-material 3D bioprinting and melt-electrospinning techniques. The performance of the scaffolds will be assessed in vitro using undifferentiated mesenchymal stem cells and other commercially available cell lines. In close collaboration with our clinical team and industrial partner, we will evaluate how to translate the newly developed product from the bench to the bed side.

肩部疼痛一次都会影响大约20％的人口。肩袖肌腱的撕裂占肩痛原因的40％。肩膀上的肩袖肌腱撕裂的当前金标准治疗方法是手术修复。但是，由于22％的病例缺乏肌腱愈合，对退化肌腱的手术修复可能失败。这种失败的风险在50至70年之间的发病率增加了一倍。因此，当前治疗方法与潜在的病理之间存在断开连接，因为对骨骼肌腱的机械缝合会导致大部分患者失败。该项目旨在提供一种基于脚手架的新疗法，并具有增强的生物学特性，以支持撕裂肌腱的功能再生并提高愈合率。在先前工作的基础上，我们将产生来自细菌起源的生物材料（即多羟基甲基酸酯-PHAS），具有可调组成和抗细菌特征，以模仿天然骨/肌腱组织的生物学，化学和物理特性。为了改善缺陷部位的生物力学耦合并增强功能再生，我们将使用能够复制天然肌腱/骨界面的印记功能梯度来制造脚手架。这将使用多物质3D生物打印和熔融 - 电纺丝技术来实现。使用未分化的间充质干细胞和其他市售细胞系在体外评估支架的性能。在与我们的临床团队和工业合作伙伴的密切合作中，我们将评估如何将新开发的产品从长凳转换为床一侧。